CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE
|
|
|
référence |
chimiothérapie |
n |
(stIV) |
% RO |
p |
SM |
p |
|
Le Chevalier, 1994 (1) |
I. Navelbine |
206 |
(102) |
14 |
0,001 |
31 s |
0,08 |
|
II. Idem + CDDP (120 mg/m2) |
206 |
(97) |
30 |
40 s |
|||
|
III. Vindesine + CDDP (120 mg/m²) |
200 |
(109) |
19 |
32 s |
|||
|
Comella, 1996 (2) |
I. CDDP-VP16 |
53 |
|
28 |
NS |
31 s |
NS |
|
II. CDDP-
CBDCA - VP16 -VNR |
52 |
|
25 |
27 s |
|||
|
Colucci, 1997(3) |
I.
CDDP+VNR puis Ifo+epirubicine |
53 |
|
47 |
0,01 |
9 m |
0,33 |
|
II.
Ifo+epirubicine puis CDDP+VNR |
47 |
|
21 |
7 m |
|||
|
Martoni, 1998 (4) |
I. CDDP (60 mg/m² J1) +
Epirubicine |
112 |
44 |
32 |
NS |
10 m |
0,09 |
|
II. CDDP(60 mg/m² J1) +
Vinorelbine |
116 |
44 |
27 |
9 m |
|||
|
Baldini, 1998 (5) |
I. CDDP-VDS-MMC |
49 |
|
14 |
NS |
8,8 m |
|
|
II. CDDP-Ifo-VNR |
48 |
|
17 |
8,8 m |
|||
|
III. CBDCA-VNR |
43 |
|
14 |
7,4 m |
|||
|
Comella, 1999 (6) |
I. CDDP (50 mg/m² J1) + gemci (1,5 g/m² J1+8) + vinorelbine (25 mg/m² J1+8) |
87 |
46 |
60 |
? |
33 s |
? |
|
II. CDDP (80 mg/m²) + épirubicine
(80 mg/m²) + vindésine (3 mg/m²) + lonidamine |
54 |
32 |
37 |
32 s |
|||
|
Perry, 2000 (7) |
I. PAC+Ifo |
48 |
|
38 |
|
8,5 m |
|
|
II. VNR+Ifo |
45 |
|
31 |
7,4 m |
|||
|
Comella, 2000 (8) |
I. CDDP+GEM+VNR |
60 |
|
47 |
? |
51 s |
? |
|
II. CDDP+VNR |
60 |
|
25 |
35 s |
|||
|
III. CDDP+GEM |
60 |
|
30 |
42 s |
|||
|
Frasci, 2000 (9) |
I. GEM+VNR |
60 |
|
22 |
NS |
29 s |
< 0,01 |
|
II. VNR |
60 |
|
15 |
18 s |
|||
|
Gridelli, 2001(10) |
I. GEM+VNR |
49 |
|
18 |
NS
|
? |
|
|
II. GEM |
44 |
|
18 |
? |
|||
|
Kelly, 2001 (11) |
I.CDDP (100 mg/m²) + VNR |
202 |
|
28 |
NS |
8,1 m |
NS |
|
II.Carboplatine (AUC 6) + paclitaxel
(225) |
206 |
|
26 |
8,6 m |
|||
|
Scagliotti, 2002 (12) |
I. CDDP (75 mg/m²) + gemcitabine |
205 |
81% |
30 |
|
9,8 m |
NS |
|
II. Carboplatine (AUC 6) + paclitaxel
(225) |
201 |
82% |
32 |
9,9 m |
|||
|
III. CDDP (100 mg/m²) + VNR |
201 |
81% |
30 |
9,5 m |
|||
|
Greco, 2002 (13) |
I. CBDCA
(AUC 5)+paclitaxel (200)+ gemci |
71 |
(51) |
37 |
NS |
9,2 m |
NS |
|
II. CBDCA
(AUC 6)+paclitaxel (200)+ VNR |
65 |
(51) |
45 |
8,6 m |
|||
|
III.
paclitaxel (200)+ gemci |
64 |
(53) |
32 |
8,7 m |
|||
|
IV. Gemci
+ VNR |
67 |
(49) |
33 |
10,7 m |
|||
|
Perol, 2002 (14) |
I. docetaxel (100)~CDDP-VNR |
38 |
tous |
11 |
|
29 s |
|
|
II. CDDP-VNR |
32 |
25 |
43 s |
||||
|
Gebbia, 2003 (15) |
I. CDDP + gemcitabine |
138 |
(73) |
34 |
0.007 |
8,2 |
NS |
|
II. CDDP + vinorelbine |
140 |
(75) |
44 |
9,0 |
|||
|
III. Ifo + gemcitabine puis CDDP + VNR |
60 |
(33) |
19 |
|
|
||
|
IV. CDDP + VNR puis Ifo + gemcitabine |
60 |
(31) |
31 |
|
|||
|
Gridelli, 2003(16) |
I. VNR |
233 |
71% |
18 |
NS |
36 s |
NS |
|
II. gemcitabine |
233 |
70% |
16 |
28 s |
|||
|
III. VNR +
gemcitabine |
232 |
69% |
21 |
30 s |
|||
|
Comella, 2004(17) |
I. Gemcitabine + paclitaxel |
65 |
(40) |
32 |
0,01 |
9,2 m |
NS |
|
II. Gemcitabine + vinorelbine |
68 |
(40) |
23 |
9,7 m |
|||
|
III. Paclitaxel |
63 |
(47) |
13 |
6,4 m |
|||
|
IV. Gemcitabine |
68 |
(44) |
18 |
5,1 m |
|||
|
Martoni, 2005(18) |
I. CDDP (75) + VNR |
137 |
65 % |
32 |
NS |
11 m |
NS |
|
II. CDDP (65) + gemcitabine |
135 |
56 % |
27 |
11 m |
|||
|
Yasuda, 2006 (19) |
I. CDDP + VNR + nitroglycérine |
60 |
34 |
72 |
<0,001 |
413 j |
<0,001 |
|
II. CDDP + VNR |
60 |
38 |
42 |
289 j |
|||
|
Hirsh, 2007 (20) |
I. VNR oral |
126 |
85 % |
4 |
|
30 s |
0,03 |
|
II. VNR iv |
63 |
81 % |
13 |
39 s |
Références
(1) Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients . J Clin Oncol 1994; 12(2):360-367.
(2) Comella P, Frasci G, De Cataldis G, Panza N, Cioffi R, Curcio C et al. Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small- cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano. Br J Cancer 1996; 74(11):1805-1811.
(3) Colucci G, Gebbia V, Galetta D, Riccardi F, Cariello S, Gebbia N. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM). Br J Cancer 1997; 76(11):1509-1517.
(4) Martoni A, Guaraldi M, Piana E, Strocchi E, Petralia A, Busutti L et al. Multicenter randomized clinical trial on high-dose epirubicin plus cis- platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer. Lung Cancer 1998; 22(1):31-38.
(5) Baldini E, Tibaldi C, Ardizzoni A, Salvati F, Antilli A, Portalone L et al. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP). Br J Cancer 1998; 77(12):2367-2370.
(6) Comella P, Frasci G, Panza N, Manzione L, Lorusso V, Di Rienzo G et al. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group. J Clin Oncol 1999; 17(5):1526-1534.
(7) Perry MC, Ihde DC, Herndon JE, Grossbard ML, Grethein SJ, Atkins JN et al. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer 2000; 28(1):63-68.
(8) Comella P, Frasci G, Panza N, Manzione L, De Cataldis G, Cioffi R et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000; 18(7):1451-1457.
(9) Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000; 18(13):2529-2536.
(10) Gridelli C, Cigolari S, Gallo C, Manzione L, Ianniello GP, Frontini L et al. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients. Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001; 31(2-3):277-284.
(11) Kelly K, Crowley J, Bunn PA, Jr., Presant CA, Grevstad PK, Moinpour CM et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19(13):3210-3218.
(12) Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S et al. Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2002; 20(21):4285-4291.
(13) Greco FA, Gray JR, Jr., Thompson DS, Burris HA, III, Erland JB, Barton JH, Jr. et al. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial. Cancer 2002; 95(6):1279-1285.
(14) Perol M, Lena H, Thomas P, Robinet G, Fournel P, Coste E et al. Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study. Ann Oncol 2002; 13(5):742-747.
(15) Gebbia V, Galetta D, Caruso M, Verderame F, Pezzella G, Valdesi M et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2003; 39(2):179-189.
(16) Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95(5):362-372.
(17) Comella P, Frasci G, Carnicelli P, Massidda B, Buzzi F, Filippelli G et al. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer 2004; 91(3):489-497.
(18) Martoni A, Marino A, Sperandi F, Giaquinta S, Di Fabio F, Melotti B et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005; 41(1):81-92.
(19) Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2006; 24(4):688-694.
(20) Hirsh V, Desjardins P, Needles BM, Rigas JR, Jahanzeb M, Nguyen L, et al. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial. Am J Clin Oncol 2007 Jun;30(3):245-51.